This House of Representative Just Bought Up To $375K In Biogen Stock - Benzinga
📈 Representative Maria Elvira Salazar purchased between $115,010 and $375,000 worth of Biogen (NASDAQ: BIIB) shares on May 11, 2026.
📊 The representative has made 68 trades totaling over $3.57 million in the past three years, with Biogen being a frequent target.
💰 Previous Biogen transactions by Salazar included purchases ranging from $50,001 to $100,000 prior to this latest filing.
📉 Current Biogen shares are trading at $195.34, up 1.41% as of the report's publication date.
⚖️ The trade is filed under the STOCK Act requirements, mandating disclosure within 45 days of the transaction date.
🏛️ Salazar also holds positions in IBM and Civitas Resources among her recent congressional trading activities.
Bullish Signals
- Representative Salazar has made a substantial new purchase of Biogen stock, indicating an expectation that the share price may rise.
- This is the largest single transaction mentioned for Biogen by this representative in the provided text, valued up to $375,000.
- The representative has a history of trading Biogen, having previously bought between $50k and $100k in prior transactions.
Full Analysis
Representative Maria Elvira Salazar of Florida filed a transaction report indicating a purchase of Biogen (NASDAQ: BIIB) shares valued between $115,010 and $375,000. The trade was executed on May 11, 2026, with the filing recorded in June 2026. This represents one of several significant positions held by the representative over the past three years.
Over the last three years, Representative Salazar has executed a total of 68 stock trades involving more than $3.57 million in value. Her portfolio includes other notable holdings such as Civitas Resources and IBM, with previous Biogen transactions ranging from $50,001 to $100,000. The current market price for Biogen shares is noted at $195.34, reflecting a 1.41% gain.
The article contextualizes these moves within the STOCK Act of 2012, which mandates that members of Congress disclose trades to prevent insider trading and personal gain from non-public information. While congressional purchases are not definitive buy signals, they often suggest an expectation of future price appreciation. The report serves as a government news update highlighting specific legislative stock activities rather than providing fundamental analysis of Biogen's business operations.
